UNSPSC 51413102: Buquineran

This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C20H29N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AWC1VMS3HC, chemically known as 1-butyl-3-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl)urea but generally known as buquineran, which bears US NIH Compound Identifier 71953. European Medicines Agency schedules Buquineran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05986MIG.

UNSPSC 51413102 Buquineran, a Commodity code, encompasses emergency medical and pharmaceutical supplies that state and local governments purchase for fire rescue services, hospital systems, and public health programs. State and local jurisdictions soliciting under this code seek specific pharmaceutical products — epinephrine, adenosine, diltiazem, labetalol, and generic multi-source medications — with strict expiration-date guarantees, rapid delivery windows, and full compliance with OSHA Hazard Communication Standards and FDA manufacturing practices. Issuing bodies include city purchasing departments (Tampa Fire Rescue procurement), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). The code reflects a mix of direct municipal emergency-services procurement and statewide coordinated purchasing vehicles designed to aggregate demand across jurisdictions.

Recent activity spans Florida, Texas, and the Upper Midwest. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026, a sealed-bid procurement for four Advanced Life Support Medications line items (370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, and related items) with delivery required within ten calendar days and an estimated contract value of $40,000.00; the bid response deadline was April 8, 2026, with a Small Local Business Enterprise (SLBE) sheltered-market designation offering a 5 percent bid discount not to exceed $10,000. The Minnesota Department of Administration issued RFP S1070000015802 for generic multi-source pharmaceuticals and over-the-counter products through the MMCAP cooperative purchasing vehicle, due March 26, 2026, requiring vendors to contract with AmerisourceBergen (Cencora), Cardinal Health, or Morris & Dickson as authorized wholesalers and establish pricing through multiple net-price formats or WAC-minus structures. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state interest in alternative pharmaceutical supply-chain arrangements outside traditional pharmacy benefit managers and group purchasing organizations.